Key players in the market include Novo Nordisk, Eli Lilly, Sanofi, Boehringer Ingelheim, AstraZeneca, Merck & Co., Bristol-Myers Squibb, and Amgen
This study was an observational cohort investigation using electronic health record data from the United States Department of Veterans Affairs and included 606,434 patients with type 2 diabetes who newly started either a GLP-1 medication or, as a comparator, a sodium-glucose cotransporter-2 inhibitor (a type 2 diabetes medication that doesnt affect appetite and reward pathways) based on filled outpatient pharmacy records
No bloating, no GI cramping, no pulling water away from your muscles
Cilt etkileri genellikle drt ila sekiz hafta iinde gzlemlenir
Interestingly, Kulak et al